Nexplanon Removal: Subcutaneous vs. Topical Lidocaine
Phase 4
- Conditions
- Contraception
- Interventions
- Drug: Subcutaneous Lidocaine
- Registration Number
- NCT04467125
- Lead Sponsor
- Augusta University
- Brief Summary
A randomized trial of using EMLA cream for anesthesia to remove Nexplanon versus the standard route of subcutaneous lidocaine for anesthesia. Primary endpoints are pain during procedure and time to removal.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
- Females with Nexplanon implant in place, desiring removal No allergy to lidocaine or any component of EMLA cream Age greater than or equal to 18years English as primary language Not pregnant
Exclusion Criteria
- pregnant non-emglish speaking age less than 18 yo Allergy to lidocaine or EMLA
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Subcutaneous Lidocaine Subcutaneous Lidocaine Subjects randomized to subcutaneous lidocaine have 1% lidocaine injected at the removal site and then undergo Nexplanon removal. EMLA Eutectic Lidocaine Prilocaine Subjects randomized to EMLA receive one inch of EMLA cream placed at the removal site and then have an occlusive dressing placed. One hour later they have the Nexplanon device removed.
- Primary Outcome Measures
Name Time Method pain of procedure during procedure Using the pain scale the participant is asked to circle the numerical value of pain they had during removal.
time to perform procedure procedure the medical assistant times the procedure from incision to removal of the device.
- Secondary Outcome Measures
Name Time Method How likely to recommend their anesthetic? procedure Provider's sense of ease of removal? procedure
Trial Locations
- Locations (1)
Augusta University Ob/Gyn Resident Continuity Clinic
🇺🇸Augusta, Georgia, United States